Annexon (ANNX) Q2 2026 Earnings Call Transcript

Annexon (ANNX) reported Q2 2026 earnings with R&D expenses of $46.6M, G&A expenses of $10.6M, and a net loss of $55.3M. The company has $209.2M in cash and a $200M credit facility. Key updates include ARCHER II trial progress in geographic atrophy and plans for a BLA submission for tanruprubart in Q4 2026. Management projects funding into 2028.

Original reporting
Published Aug 22, 2026, 2:16 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 22, 2026, 5:14 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Annexon (ANNX) Q2 2026 Earnings Call Transcript — source image
Decision brief

The 30-second read

$ANNXNeutralMed
01

Why it matters

The Q2 earnings and trial updates provide fresh data for valuation and pipeline risk assessment.

02

Market read

Earnings and trial progress are primary catalysts for Annexon's stock movement.

03

What to watch

The new $200M credit facility provides runway, reducing near-term financing risk.

Relevance 7/10Novelty 7/10Timing: pre-market today

Background

Annexon is a clinical-stage biotech focusing on complement inhibition for rare diseases.

Company-level read

Ticker impact

$ANNXNeutralHigh confidence
Context

Annexon reported Q2 2026 financial results, including a net loss of $55.3M and a $200M credit facility, plus clinical updates on ARCHER II and GBS programs.

Expected impact

Potential short-term volatility as investors digest higher losses versus long runway and clinical progress; upside if trial data remains positive.

Evidence & confidence

Financials are material for valuation; clinical updates are material for biotech catalysts.

Market effects

Biotech sector may see increased interest in complement inhibition therapies.

U.S. biotech investors may adjust exposure to early-stage ophthalmology and neurology assets.

Clinical data could influence global partners and competitors in GBS and geographic atrophy treatments.

Counterpoint

Higher cash burn and net loss may outweigh trial enrollment gains, suggesting caution.

Key entities

  • Douglas Love

    President and CEO of Annexon

  • ARCHER II

    Phase III geographic atrophy trial with expanded enrollment

Related articles

$ANNXHigh

Wells Fargo Names Top Pick in Biotechnology Sector

Wells Fargo named Annexon, Inc. its top biotech pick, maintaining an Overweight rating and $27.00 price target. The firm cited the company's ARCHER II trial for vonaprument in generalized myasthenia gravis (GA) as a key catalyst, with a 55% success probability. Annexon has near-term catalysts, including a Q4 2026 data readout and a BLA submission. The company has $213M in cash and a $200M credit facility. Shares are down 16% YTD, underperforming the SPDR S&P Biotech ETF's 29% gain.

$ANNXMed

Annexon Reports Third Quarter 2026 Financial Results, Business Updates and Key Anticipated Milestones

Annexon, Inc. (ANNX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Annexon Reports Third Quarter 2026 Financial Results, Business Updates and Key Anticipated Milestones Differentiated C1q Platform Advances Two Registrational Programs with Blockbuster Potential, Driving Near-Term Value Catalysts Tanruprubart U.S./EU FORWARD Data in G

$ANNXMed

H.C. Wainwright raises Annexon stock price target on GBS approval prospects

H.C. Wainwright raised its price target for Annexon Biosciences (ANNX) to $25, citing catalysts like the tanruprubart BLA submission for GBS and ARCHER II readout for vonaprument. The firm values these at $11.70 and $13.60 per share, respectively. ANNX trades at $3.96, down 38% in six months, with a strong balance sheet but high cash burn. Recent Q2 loss was $0.28 per share. Other analysts also raised targets and ratings.

$ANNXMedAI 8/10

Annexon (ANNX) Q2 2026 Earnings Call Transcript

Annexon (ANNX) reported Q2 2026 earnings with R&D expenses of $46.6M, G&A expenses of $10.6M, and a net loss of $55.3M. The company has $209.2M in cash and a $200M credit facility. ARCHER II trial for geographic atrophy enrolled 659 patients, exceeding targets. Tanruprubart for Guillain-Barré syndrome (GBS) is on track for BLA submission in Q4 2026, with positive FORWARD study data. Operations are funded into 2028.